Alpine Immune Sciences — Investor Presentation (September 2018)
27 slides from Alpine Immune Sciences's investor presentation, Sep 25, 2018
Slide 1: Creating New Immunotherapies to Fight Disease
Creating New Immunotherapies to Fight Disease September, 2018 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not base
Slide 3: Leading the Next Wave of Immunotherapies
Leading the Next Wave of Immunotherapies PLATFORM TECHNOLOGY Powerful platform technology to be leveraged for strategic partnerships and licensing opportunities Alpine’s lead programs in inflammation and oncology targeted to enter the clinic in 2019 MANAGEMENT TEAM Proven development, regulatory and
Slide 4: Using Directed Evolution to Create Powerful Multifunctional Immunotherapies
IgSF proteins are the largest family of adhesion, activating, and inhibitory proteins on immune system cells. They are broadly involved with the recognition of antigens and performing costimulatory, co‑inhibitory, and cytokine receptor functions The distinctive ability of vIgDs to engage multiple ta
Slide 5: Two Lead Programs: ALPN-101 & ALPN-202
TWO LEAD PROGRAMS ALPN-101 & ALPN-202 POWERFUL SCIENTIFIC PLATFORM FOCUS ON DELIVERING VALUE
Slide 6: ALPN-101 Autoimmune/Inflammatory Diseases
ALPN-101 Autoimmune/Inflammatory Diseases
Slide 7: New Approaches Needed for Better Autoimmune Therapies
New Approaches Needed for Better Autoimmune Therapies New therapeutic options needed for a host of other potentially ICOS/CD28 mediated diseases: Lupus, Sjogren’s syndrome, Inflammatory Bowel disease (IBD), Ocular (Uveitis/Dry Eye), and Fibrosis Psoriatic Arthritis Acute GvHD ~250-300K patients per
Slide 8: Strong Biological Rationale for Inhibition of Both CD28 and ICOS
Strong Biological Rationale for Inhibition of Both CD28 and ICOS Naïve T cell CD28+ ICOS- CD28+ ICOS+ T cell activation: ICOS CD28 ¯ (some cells) CD28- ICOS+ CD28lo ICOS+ Activated / Effector / Memory / FH T cells Various populations Encouraging clinical data with single pathway blockade in multip
Slide 9: ALPN-101 First in Class Dual ICOS/CD28 Antagonist
ALPN-101 First in Class Dual ICOS/CD28 Antagonist ALPN-101 is a first in class dual ICOS/CD28 antagonist Large market opportunity in multiple indications Designed to target disease indications where single blockade has failed Company data
Slide 10: ALPN-101 Preclinical Data Show Efficacy Across Multiple Disease Models
ALPN-101 Preclinical Data Show Efficacy Across Multiple Disease Models IBD: Adoptive Transfer Model Humanized GVHD Arthritis: Preventative and Therapeutic Dosing Preventative Dosing Therapeutic Dosing Multiple Sclerosis Collagen-Induced Arthritis MOG Adoptive Transfer Experimental Autoimmune Encepha
Slide 11: Significant Market Opportunity Across Multiple Disease Indications
Significant Market Opportunity Across Multiple Disease Indications Rheumatology Rheumatoid Arthritis Psoriatic Arthritis Systemic Lupus Erythematosus Sjögren’s Syndrome Inflammatory Myositis Gastroenterology Crohn’s Disease Ulcerative Colitis Neuroscience Heme/Onc Acute or chronic GVHD/GVHD Preventi
Slide 12: Lead Indications for ALPN-101
Lead Indications for ALPN-101 PsA offers a considerable commercial opportunity. ~250-300K patients per year affected with moderate to severe psoriatic arthritis TNFs, IL-17s, and IL-12/23s expected to dominate market. Competitive pipeline offering few novel MOAs Orencia’s revenues are projected at $
Slide 13: Executing Initial Clinical Strategy for Lead Program ALPN-101
Executing Initial Clinical Strategy for Lead Program ALPN-101 Phase 1 Healthy Volunteer Study (AUS) Phase 2a Psoriatic Arthritis Phase 1/2 Acute GvHD Preclinical development GMP manufacturing with sufficient drug substance to complete initial Phase 1 Study Phase 2b Proof-of-concept expansion into ot
Slide 14: ALPN-202 Oncology
Acrineimmunesci ences ALPN-202 Oncology
Slide 15: ALPN-202 Provides Dual Checkpoint Blockade with T-Cell Costimulation
ALPN-202 Provides Dual Checkpoint Blockade with T-Cell Costimulation Anti PD-1/L1 Responders (<30%) Likely Have Adequate Costimulatory Ligands But Most (>70%) Do Not Respond Likely Due to Insufficient Costimulation ALPN-202 has the potential to improve responses to currently available cancer immunot
Slide 16: Promising Preclinical Data Demonstrates Elimination of Tumors
Promising Preclinical Data Demonstrates Elimination of Tumors with Persistent Anti-Tumor Immunity ALPN-202 Alone Has Better Efficacy Than a PD-L1 Antibody Company data Overall Survival ALPN-202 Treated Mice Remain Tumor-Free When Re-Challenged with Tumor Cells Human PD-L1 Transduced MC38 Tumor Model
Slide 17: Current Combination Immuno-Oncology Therapies Fail to Provide Meaningful Response
Current IO combination therapies are cornerstone to current treatment Only small percentage of patients (~20%-40%) benefit Current mindset suggests next wave will need to address co-stimulation as well as inhibiting checkpoints Current Combination Immuno-Oncology Therapies Fail to Provide Meaningful
Slide 18: ALPN-202 Clinical Strategy
ALPN-202 Clinical Strategy Objective is to quickly show treatment effect in tumor “basket” trial at therapeutic doses Limited competition compared to checkpoint inhibition space supports differentiation with early human data Favorable manufacturing and commercial profile PHASE 1 ALPN-202 Planning to
Slide 19: Two Lead Programs: ALPN-101 & ALPN-202
TWO LEAD PROGRAMS ALPN-101 & ALPN 202 POWERFUL SCIENTIFIC PLATFORM FOCUS ON DELIVERING VALUE
Slide 20: Ability to Rapidly Develop Potential Therapies from Novel Scientific Platform
Ability to Rapidly Develop Potential Therapies from Novel Scientific Platform Functional domains maintain immune synapse integrity compared to antibody approaches Ability to target multiple homologous structures has synergistic potential Alpine has generated domains from high value targets (ICOS,TIG
Slide 21: Upcoming Scientific Presentations
Upcoming Scientific Presentations October 21, 2018 ALPN-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Disease in Multiple Mouse Models of Autoimmunity October 21, 2018 Therapeutic Candidate ALPN-101, a Dual ICOS/CD28 Antagonist, Demonstrates In Vivo Efficacy in an Experimental Autoimmune Enc
Slide 22: Two Lead Programs: ALPN-101 & ALPN-202
TWO LEAD PROGRAMS ALPN-101 & ALPN 202 POWERFUL SCIENTIFIC PLATFORM FOCUS ON DELIVERING VALUE
Slide 23: Pipeline of Potential Novel Therapies
Pipeline of Potential Novel Therapies PROGRAM DISCOVERY IND-ENABLING PHASE 1 COLLABORATOR Autoimmune/Inflammatory Diseases ALPN-101 (Dual ICOS/CD28 antagonist) ALPN-101 (Dual ICOS/CD28 antagonist) Undisclosed Programs Immuno-Oncology ALPN-202 (PD-L1/CTLA-4 Antagonist-CD28 Agonist) Undisclosed Progra
Slide 24: Strong Financial Position
Strong Financial Position $69.9 million cash equivalents as of June 30, 2018 Sufficient cash runway to fund operations into 2020 ~13.9 million shares outstanding as of August, 2018 Analyst Coverage
Slide 25: Strong Leadership Team with Deep Clinical, Regulatory and Commercial Expertise
Strong Leadership Team with Deep Clinical, Regulatory and Commercial Expertise LEADERSHIP TEAM PRINCIPAL INVESTORS Mitchell H. Gold, M.D. Executive Chairman & CEO Stanford Peng, M.D., Ph.D. EVP of R&D, Chief Medical Officer Ryan Swanson VP of Immunology & Co-Founder Paul Rickey Chief Financial Offic
Slide 26: Leading the Next Wave of Immunotherapies
Leading the Next Wave of Immunotherapies PLATFORM TECHNOLOGY Powerful platform technology to be leveraged for strategic partnerships and licensing opportunities Alpine’s lead programs in inflammation and oncology targeted to enter the clinic in 2019 MANAGEMENT TEAM Proven development, regulatory, an
Slide 27: Thank You
ImmuneSciences Thank You
Alpine Immune Sciences — Investor Presentation (September 2018) on 6ix